QOL Issues in Polycythemia Vera

Emily A. Knight, RN

Video Categories: Polycythemia Vera

Emily Knight presents why quality of life is a big issue in polycythemia vera and how she helps patients in management

Supported through funding from Incyte
July 13, 2021

Significance of Early and Broad Testing of Tumor Mutations

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss how testing for tumor mutations early and broadly may lead to better treatment outcomes.

June 16, 2015

The Biomarker: Melanoma

PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.